ARROWHEAD PHARMACEUTICALS reports 2018 executive compensation

CEO Christopher Anzalone receives $1.6M

ARROWHEAD PHARMACEUTICALS reported fiscal year 2018 executive compensation information on January 25, 2019.

In 2018, five executives at ARROWHEAD PHARMACEUTICALS received on average a compensation package of $1,106,880, a 5% increase compared to previous year.

Average pay of disclosed executives at ARROWHEAD PHARMACEUTICALS

Christopher Anzalone, Chief Executive Officer, received $1,619,901 in total, which decreased by 13% compared to 2017. 60.19% of Anzalone's compensation, or $975,000, was in non-equity incentive plan. Anzalone also received $643,012 in salary and $1,889 in other compensation.

Bruce D. Given, Chief Operating Officer, received a compensation package of $1,552,061, which increased by 12% compared to previous year. 41.49% of the compensation package, or $644,000, was in stock awards.

Kenneth Myszkowski, Chief Financial Officer, earned $853,018 in 2018, a 18% increase compared to previous year.

Patrick O'Brien, General Counsel, received $823,295 in 2018, which increases by 2% compared to 2017.

Zhen Li, Senior Vice President, Chemistry and Non Clinical Development, earned $686,124 in 2018, a 36% increase compared to previous year.

ARROWHEAD PHARMACEUTICALS' fiscal year ends on September 30.